Project Grant R01HL179224
Award Date 9/1/25
Completion Date 5/31/30
Dollars Obligated $710K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33199, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Peca Labs Inc. to develop a novel, fully-polymeric, biomimetic prosthetic mitral valve. The objective is to create a valve that combines the positive characteristics of both biological and mechanical mitral valves to improve durability, performance, and patient outcomes. Peca Labs will subject the polymer leaflet material to hydrodynamic...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $742,323 to Vanderbilt University to develop a new bioprosthetic aortic valve made from the pulmonary visceral pleura (PVP) tissue. The research aims to demonstrate the PVP valve's superior mechanical durability, calcification resistance, and hemodynamic performance compared to current bioprosthetic valves, in order to improve the long-term durability of...
- The National Heart Lung and Blood Institute (NHLBI), part of the U.S. National Institutes of Health (NIH), awarded a $460,625 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University on August 10, 2025. The objective of this project is to develop highly tunable and customizable Tissue Engineered Vascular Conduits (TEVCs) using a novel bioprinting method that can directly print fully physiological materials, including cell-laden tissues. The project aims...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
- This $321,679 Project Grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and testing of an expandable pediatric pulmonary heart valve device. The research aims to create a valve that can grow larger with the patient to address the challenge of multiple open-heart surgeries required for infants and children with severe heart valve defects. The key research activities include optimizing the...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- The National Heart Lung and Blood Institute awarded a $414,982 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville Division, Office of Research & Sponsored Programs. The grant aims to enhance a surgical planning tool for heart valve procedures by developing a force-validated computational model of the mitral valve using experimental data from both healthy porcine and human valves. This research will improve the...